Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman(The University of Texas MD Anderson Cancer Center), Mark F. Brady(NRG Oncology), Thomas J. Herzog(University of Cincinnati), Paul Sabbatini(Memorial Sloan Kettering Cancer Center), Deborah K. Armstrong(Sidney Kimmel Cancer Center), Joan L. Walker(University of Oklahoma), Byoung‐Gie Kim(Samsung Medical Center), Keiichi Fujiwara(Saitama Medical University), Krishnansu S. Tewari(University of California, Irvine Medical Center), David M. O’Malley(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Susan A. Davidson(University of Colorado Denver), Stephen C. Rubin(Fox Chase Cancer Center), Paul DiSilvestro(Providence College), Karen Basen‐Engquist(The University of Texas MD Anderson Cancer Center), Helen Huang(NRG Oncology), John K. Chan, Nick M. Spirtos(Women's Cancer Center of Nevada), Raheela Ashfaq, Robert S. Mannel(University of Oklahoma)
Cited by 601Open Access
Abstract
Related Papers
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman et al.|New England Journal of Medicine|2011|2.4k